20 results about "Cell cycle progression" patented technology

The invention relates to application of a DDX39B protein inhibitor in preparation of acute leukemia treatment medicines, and belongs to the technical field of biological medicines. In order to solve the problems of single acute leukemia treatment scheme and lack of novel medicines at present, the invention provides application of a DDX39B protein inhibitor in preparation of acute leukemia treatment medicines. Targeted inhibition of DDX39B can significantly hinder proliferation of leukemia cells, promote apoptosis and differentiation of cells, retard the process of cell cycles, delay disease progression in vivo and prolong the lifetime of model animals. On the basis of an RNA (Ribonucleic Acid) binding pocket structure of DDX39B, through high-throughput drug screening, the small molecule compound HMU-4051C is firstly identified as a DDX39B targeted inhibitor to effectively kill leukemia cells, and a new application of the DDX39B protein inhibitor in preparation of acute leukemia treatment drugs is developed.

The invention relates to application of a yeast peptide-derived polypeptide in promoting proliferation and differentiation of myoblasts and a composition, and belongs to the technical field of biological medicines and nutrition and health care. The amino acid sequence of the polypeptide comprises SEQ ID No.1 (LGGPLL), SEQ ID No.2 (PQAVTI), SEQ ID No.3 (VASGGL) or SEQ ID No.4 (LGPTGISM, and the polypeptide can be used for remarkably promoting the proliferation and the cell cycle progress of C2C12 myoblasts and up-regulating the expression level of myogenic protein. The polypeptide can be used as an active component to be applied to development of anti-sarcopenia related medicines or functional food compositions. Cell experiments prove that the polypeptide has a good muscle promoting function and is suitable for intervention of senile muscle loss such as sarcopenia and the like.

The application discloses application of PGD2 in promoting rumen development of young ruminants, and application of PGD2 in young ruminants promotes proliferation and differentiation of rumen wall cells, and further promotes rumen development and improves the digestive and absorptive capacity of the rumen. 2+ It is found that PGD2 can promote rumen development by activating Ca signal pathways, promoting expression of CAMK2A protein, promoting cell cycle progression, promoting rumen development, and ensuring animal health. Therefore, PGD2 can be used for preparing a medicine for promoting rumen development of young ruminants.

The invention discloses a probiotic which is derived from human milk and has the effects of resisting oxidation, resisting inflammation, protecting tissues and protecting intestinal barriers and application of the probiotic. Lactobacillus paracasei DPUMW-M14-9 is preserved in the general microbiological center of the China Committee for Culture Collection of Microorganisms, and the preservation number is CCTCC M 20252990. The strain has the characteristics of acid resistance, bile resistance, strong oxidation resistance, high surface hydrophobicity, self-aggregation capability and the like. The lactobacillus paracasei DPUMW-M14-9 can effectively adhere to epithelial cells, promote cell proliferation and regulate and control the process of a cell cycle. The bacterial strain can be used for inhibiting proinflammatory cytokines (TNF-alpha, IL-6 and IL-1beta) induced by lipopolysaccharide (LPS) and repairing tight junction proteins (ZO-1, Occludin and Claudin-1) at the same time, so that the integrity of epithelial cells is enhanced.

The invention belongs to the field of biological medicine, particularly relates to application of a VIRMA inhibitor in preparation of a medicine for treating colorectal cancer, and finds that the expression level of VIRMA in the colorectal cancer is remarkably increased and is closely related to poor prognosis. Further experiments prove that the VIRMA can significantly enhance the proliferation and migration ability of colorectal cancer cells, accelerate the progress of a cell cycle and inhibit cell apoptosis. Meanwhile, m6A modification is carried out on RNA (Ribonucleic Acid) of STING by VIRMA under mediation of YTHDF2 so as to reduce the stability of STING mRNA (Messenger Ribonucleic Acid), so that malignant progression and immune escape of colorectal cancer are promoted.

This invention discloses a monoclonal antibody targeting NECTIN4, its associated nucleic acid, vector, host cell, and its application in the preparation of antitumor drugs, belonging to the field of biomedical technology. The monoclonal antibody comprises a specific heavy chain variable region VH and a light chain variable region VL. The HCDR1-3 amino acid sequences of VH are shown in SEQ ID NO:1-3, and the LCDR1-3 amino acid sequences of VL are shown in SEQ ID NO:4-6. This invention also provides the nucleic acid encoding the antibody (SEQ ID NO:10), a vector containing the nucleic acid, and a host cell containing the nucleic acid or the vector. This Nectin4 monoclonal antibody can specifically target and bind to the NECTIN4 protein on the surface of tumor cells, inhibiting tumor cell cycle progression, proliferation, migration, and invasion by regulating the NF-κB pathway. As a naked antibody, it exhibits significant tumor-targeting inhibitory effects, especially for esophageal cancer, and can also be used for targeted therapy of other malignant tumors such as breast cancer and lung cancer. This monoclonal antibody has a better safety profile than ADC drugs, providing a new option for tumor targeted therapy.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a ubiquitin specific peptidase 13 inhibitor in preparation of a medicine for treating chronic kidney diseases. According to the present invention, as the acknowledged ubiquitin specific peptidase 13 inhibitor, the results of the in vivo unilateral ureteral ligation animal experiment and the in vitro TGF-beta 1 induced cell experiment show that the Spautin-1 can be used as the ubiquitin specific peptidase 13 inhibitor, the Spautin-1 can be used for alleviating UUO induced renal interstitial fibrosis, alleviating in-vitro TGF-beta1 induced renal fibroblast activation and regulating and controlling the cell cycle process of the TGF-beta1 induced renal fibroblast. The Spautin-1 has the advantages that the UUO induced renal interstitial fibrosis can be alleviated, and the in-vitro TGF-beta1 induced renal fibroblast activation can be alleviated; therefore, the Spautin-1 can relieve the CKD-related diseases and can be used for preparing the medicine for treating the CKD and the related diseases. The invention provides a new medicine source for relieving and treating CKD, and has a good clinical application prospect.

The invention relates to the technical field of livestock breeding biology, and discloses a method for promoting porcine ovary granular cell proliferation, which comprises the following steps: adding a porcine follicular fluid exosome into a porcine ovary granular cell culture system, and acting for a certain time at an effective concentration, so as to improve the proliferation activity of granular cells. After the exosome treatment, the apoptosis rate of granular cells can be reduced, the cell survival rate can be improved, and the granular cells can be promoted to secrete steroid hormones, including the estradiol level and the expression of progesterone synthetase. Cell experiments prove that the follicular fluid exosome can effectively improve the activity of granular cells, promote the process of a cell cycle, inhibit cell apoptosis and remarkably enhance the synthesis capacity of steroid hormones such as estradiol and progesterone, and a new intervention strategy is provided for improving follicular development and reproductive performance of sows.

The application belongs to the technical field of pharmaceutical chemistry, and particularly relates to application of 1-pentyl-tetradecahydro-1H-cyclopenta[1,2-a]phenanthrene in treatment of acute myeloid leukemia. The application provides 1-pentyl-tetradecahydro-1H-cyclopenta[1,2-a]phenanthrene compounds with a novel skeleton. Experimental verification shows that the compounds have excellent inhibitory activity on AML cancer cells, and the mechanism is clear: the compounds can directly inhibit the activity of AML cancer cells, inhibit the proliferation of cancer cells by blocking the cell cycle process, and can specifically induce AML cancer cell apoptosis, thereby realizing the AML treatment effect. The application provides a new active compound candidate for the targeted treatment of acute myeloid leukemia, and lays an important foundation for the research and development of related drugs.

This disclosure describes the characteristics of the “energetic” cancer stem cell (e-CSC) phenotype. This distinct sub-population of cancer stem cells (CSCs) has a unique energetic profile compared to bulk CSCs, being more glycolitic, having higher mitochondrial mass and elevated oxidative metabolism. e-CSCs also show an increased capacity to undergo cell cycle progression, enhanced anchorage-independent growth, and ALDH-positivity. The e-CSC phenotype presents new targets for cancer therapeutics, and in particular the anti-oxidant response, mitochondrial energy production, and mitochondrial biogenesis of e-CSCs makes them highly susceptible to mitochondrial inhibitors that target e-CSC anti-oxidant response, mitochondrial energy production, and mitochondrial biogenesis. Gene products for e-CSCs are disclosed, as well as classes of mitochondrial inhibiting therapeutic agents. Also disclosed are methods for identifying and separating e-CSCs front bulk cell populations.

The present application relates to the use of DDX39B protein inhibitor for preparing a therapeutic drug for acute leukemia, and belongs to the technical field of biological medicine. In order to solve the problem that the current treatment scheme for acute leukemia is single and new drugs are scarce, the present application provides the use of DDX39B protein inhibitor for preparing a therapeutic drug for acute leukemia. The present application discloses that targeted inhibition of DDX39B can significantly hinder the proliferation of leukemia cells, promote cell apoptosis and differentiation, block cell cycle progression, and delay disease progression and prolong the survival of model animals in vivo. Based on the RNA binding pocket structure of DDX39B, through high-throughput drug screening, the present application first identifies a small molecule compound HMU-4051C as a DDX39B targeted inhibitor that effectively kills leukemia cells, and develops a new use of DDX39B protein inhibitor in preparing a therapeutic drug for acute leukemia.

The invention belongs to the technical field of biological medicines, and particularly relates to application of ZBTB20 as a prognostic marker or a treatment target of non-early precursor T acute lymphocytic leukemia. The invention finds that a tumor inhibition factor BACH2 participates in transcriptional inhibition regulation and control by combining with a section of MARE sequence in a ZBTB20 gene promoter, and interference on expression of ZBTB20 can promote apoptosis of non-ETP ALL cells and slow down a leukemia cell cycle process, so that growth of the non-ETP ALL cells is inhibited, which indicates that the ZBTB20 plays a role of a cancer promoting factor in the non-ETP ALL cells. Finally, clinical data analysis shows that ZBTB20 gene high expression prompts poor prognosis of non-ETP ALL patients. The ZBTB20 gene or the encoded protein thereof can be used as a prognostic marker and a therapeutic target of the non-ETP ALL.

The invention relates to the technical field of lung adenocarcinoma, and particularly discloses a biomarker for early diagnosis and treatment of LUAD and application of the biomarker. The biomarker combination comprises an I GF2BP3 gene and an HJURP gene, the invention discloses an application of a biomarker combination in preparation of an LUAD early diagnosis kit, an application of the biomarker combination in preparation of a lung adenocarcinoma early diagnosis product and an application of the biomarker combination in preparation of a lung adenocarcinoma treatment drug. The invention discloses that I GF2BP3 enhances the stability of HJURP mRNA through an m6A dependency mode, promotes the expression of HJURP protein and improves the immunogenicity of the HJURP. Therefore, the proliferation, migration and cell cycle progress of lung adenocarcinoma are driven, and the mechanism blank of m6A modification regulation of the action of HJURP in lung cancer is filled.

The invention discloses a composite probiotic fermentation method and application, and belongs to the technical field of fermentation. Saccharomyces cerevisiae and kluyveromyces marxianus are used as compound probiotics for fermentation to prepare a compound yeast culture, the compound yeast culture and a plant extract form a compound, and the compound shows a synergistic interaction effect, specifically, the rumen papillary protrusion length and the rumen surface area are increased, the cell cycle progress is accelerated, and the effect of improving the rumen papillary protrusion length and the rumen surface area is achieved. Compared with the prior art, the rumen epithelial cell culture medium has the advantages that the density of living cells is higher, rumen epithelial cell proliferation is promoted, the expression of apoptosis related genes caspase 3, Cyt-c, Fas and TNFR1 is remarkably reduced, and the apoptosis of rumen epithelial cells is relieved. The method not only has practical value for comprehensive utilization of the compound yeast culture obtained by fermentation of the compound probiotics, but also has important value for promoting ruminant rumen epithelium development.

The invention relates to the technical field of breast cancer precision medical treatment, and discloses a double-variable simulation analysis system based on DNA content and cell cycle related protein. Comprising a sample processing module used for obtaining a breast cancer tumor cell sample and carrying out fluorescence labeling processing on the sample; the double-variable detection module is used for detecting the DNA content and the protein expression quantity so as to generate double-variable data points of the DNA content and the protein expression of each breast cancer tumor cell sample; the control module is used for analyzing a time difference between cell cycle related protein expression and DNA content change through a quasi-time sequence algorithm based on the bivariate data points, and constructing a time sequence function model reflecting a cell cycle process; and fitting the time sequence function model to generate a cell cycle dynamic curve, and pre-judging the drug resistance and prognosis of the breast cancer cells according to the abnormal characteristics of G1 / S phase transition nodes in the cell cycle dynamic curve, the overexpression level of cell cycle protein E and the abnormal stagnation proportion of S phase cells.

The invention discloses a hepatocellular carcinoma prognosis evaluation marker TKFC and application thereof, and belongs to the technical field of prognosis markers. By comparing tumor tissues of patients with different prognosis, the invention discovers that the HCC subtype with relatively strong invasiveness shows a systematic state imbalance, that is, the oxidative metabolism function represented by mitochondrial oxidative phosphorylation and tricarboxylic acid cycle is weakened, and the intracellular proliferation procedure related to chromatin remodeling and cell cycle progress is abnormally active. The state of low oxidative metabolism-high proliferation output may form the metabolism and epigenetic basis of malignant HCC. The low expression of the TKFC is obviously related to high-risk clinical pathological characteristics such as later tumor staging and higher occurrence rate of vascular invasion, and is an independent poor prognosis factor influencing the total lifetime of a patient, which indicates that the TKFC can be used as a prognosis biomarker of HCC.

This invention relates to the field of biomedical technology, and more particularly to the use of a combination of RVX208 and temozolomide for the treatment of glioblastoma. It also relates to the use of RVX208 to resensitize temozolomide-resistant cancers to temozolomide treatment. The use of at least one of RVX208, a pharmaceutically acceptable salt of RVX208, a solvate of RVX208, a hydrate of RVX208, a polymorph of RVX208, an isomer of RVX208, a prodrug form of RVX208, and temozolomide in the preparation of a glioblastoma therapeutic agent. RVX208 inhibits the transcriptional activity of various genes related to cell cycle progression and proliferation maintenance by inhibiting BET family proteins or other target molecules, leading to cell cycle arrest, inhibition of cell proliferation, and induction of programmed cell death. RVX208 also interferes with the transcriptional expression of genes related to mitochondrial homeostasis regulation, resulting in a decrease in mitochondrial membrane potential and reduced ATP production, thus enabling RVX208 to disrupt mitochondrial function in GBM cells and produce a synergistic antitumor effect with temozolomide.

The present invention relates to the use of UPP1 inhibitors in the preparation of drugs for treating psoriasis, and belongs to the field of biomedicine technology. The present invention uses imiquimod to induce the formation of a psoriasis animal model, and administers the UPP1 inhibitor 5-cyano-4-methyl-6-oxo-1,6-dihydropyridine-2-olate potassium (CPBMF65) by oral gavage, and then detects its therapeutic effect on psoriasis. The results show that oral gavage of CPBMF65 can significantly alleviate psoriasis symptoms. The present invention discloses for the first time the role of uridine phosphorylase-1 in promoting the cell viability and cell cycle progression of HaCaT cells through the glycolysis pathway in the pathogenesis of psoriasis, providing a new drug source for the treatment of psoriasis while opening up a new application field for the application of CPBMF65.

The invention discloses an OASL mutant haplotype gene of Jingmen green-shell laying hens and application of the OASL mutant haplotype gene in regulation and control of cell growth, and belongs to the technical field of gene engineering. According to the invention, an OASL mutant haplotype gene is identified in a Jingmen green-shell laying hen group, and the nucleotide sequence of the OASL mutant haplotype gene is shown as SEQ ID NO.4. Compared with a wild type gene, the mutant haplotype gene can remarkably improve the cell activity, improve the cell cycle progress and lower the expression of apoptosis-related factors, and has important significance on enhancing the cell proliferation capacity and inhibiting cell apoptosis. According to the invention, a theoretical basis is provided for research on cell proliferation and apoptosis mechanisms of the Jingmen green-shell laying hens, a technical support is provided for construction of a high-activity cell model, and a new genetic resource is provided for identification of animal growth performance and molecular assisted breeding.

The present disclosure provides, among other things, methods of classifying prostate cancer, methods of analyzing a prostate tumor sample, and methods of selecting a subject for removal and dissection of lymph nodes in the pelvis (PLND). Such methods can comprise detecting an expression level for one or more genes in a panel of cell cycle progression (CCP) genes and providing a clinical cell-cycle risk (CCR) score from the expression level of the genes in the panel of CCP genes and a Cancer of the Prostate Risk Assessment (CAPRA) score.